๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate)

โœ Scribed by Nigel M. Kimber; Peter F. Marriott; Trevor R. Norman; Graham D. Burrows

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
394 KB
Volume
1
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

โœฆ Synopsis

Plasma fluphenazine concentrations were measured by neuroleptic radioreceptor assay in 17 outpatients receiving chronic treatment with intramuscular fluphenazine decanoate. The range of concentrations was 0.5-2.4 pglL over the dosage range of 0.30-3.2 mg/d. Age, sex and smoking status had no influence on plasma fluphenazine concentrations, which were not correlated with dose (expressed as mg/kg/d). There was no significant correlation between plasma concentration and clinical status of the patients. No difference in plasma concentration between patients with extrapyramidal signs or tardive dyskinesia and those without signs were observed.

๐Ÿ“œ SIMILAR VOLUMES

Fluphenazine plasma levels in patients r
Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate
โœ Stephen R. Marder; Edward M. Hawes; Theodore Putten; John W. Hubbard; Gordon McK ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› Springer ๐ŸŒ English โš– 487 KB

Plasma fluphenazine concentrations (FLU) were measured in 45 patients with schizophrenic disorders who participated in a double-blind comparison of 5 and 25 mg fluphenazine decanoate (FD). The rise in plasma level of FLU 24 h after a "test dose" was significantly correlated with steady state FLU con

Early unwanted effects of fluphenazine e
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients
โœ A. C. Altamura; S. H. Curry; S. Montgomery; D. H. Wiles ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer ๐ŸŒ English โš– 381 KB

Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary movement